3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

41.95 +0.50 ( +1.21% ) 4:02 12/10/18 Pricing delayed 20 minutes

Volume 848,889

Recent News

See All
November 5, 2018 Nevro Reports Third Quarter 2018 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and nine months ended September 30, 2018. Third Quarter Financial Results Revenue for the three months ended September 30, 2018 was $95.6 million versus $82.3 million during the same period of the prior year, representing 16% growth as reported. U.S. revenue for the three months ended September 30, 2018 was $79.6 million, representing 20% growth. International revenue was $16.0 million, representing growth of 4% in constant currency. The increase in revenue was primarily attributable to the continued adoption of the Senza system. Gross profit for the three months ended September 30, 2018 was $67.2 million, representing a 70% gross margin, up from $57.9 million, representing a 70% gross margin, in the same period of the prior year. Operating expenses for the three months ended September 30, 2018...
October 11, 2018 Nevro to Report Operating Results for the Third Quarter 2018
Nevro to Host Conference Call on Monday, November 5, 2018 at 1:30 p.m. PT / 4:30 p.m. ET  Nevro Corp. (NYSE: NVRO), a global medical technology company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results for the third quarter of 2018 after market close on Monday, November 5, 2018. Company management will host a conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Monday, November 5, 2018. Investors interested in listening to the conference call may do so by dialing (833) 286-5807 for U.S. callers or (647) 689-4452 for international callers (Conference ID: 3989464), or logging into the webcast on the "Investors" section of the Company's website at www.nevro.com/investors. Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website. About Nevro Headquartered in Redwood City, California, Nevro is a global...
September 17, 2018 Nevro Receives TGA Approval for Senza II(TM) Spinal Cord Stimulation System Delivering HF10(TM) Therapy
SUPERIOR THERAPY NOW DELIVERED IN A SMALLER AND MORE REFINED IPG REDWOOD CITY, California, Sept. 17, 2018 /PRNewswire-AsiaNet/ - Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that it has received TGA approval for its next-generation Senza II(TM) Spinal Cord Stimulation (SCS) System delivering HF10(TM) therapy. The Senza II system offers the superior outcomes and clinical advantages of HF10 therapy through a smaller and more refined footprint while maintaining the performance, durability, and full-body magnetic resonance imaging (MRI) conditional labelling of the current Implantable Pulse Generator (IPG). "My colleagues and I are excited about the approval of the Senza II SCS system," said Dr. Paul Verrills, Director of Metro Pain Group in Melbourne, Australia. "The reduced size and optimized design of the Senza II IPG allow for greater patient comfort and placement...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.